Baxdrostat

Last updated
Baxdrostat
Baxdrostat.svg
Identifiers
  • N-[(8R)-4-(1-methyl-2-oxo-3,4-dihydroquinolin-6-yl)-5,6,7,8-tetrahydroisoquinolin-8-yl]propanamide
CAS Number
PubChem CID
IUPHAR/BPS
ChemSpider
UNII
KEGG
ChEMBL
Chemical and physical data
Formula C22H25N3O2
Molar mass 363.461 g·mol−1
3D model (JSmol)
  • CCC(=O)N[C@@H]1CCCC2=C1C=NC=C2C3=CC4=C(C=C3)N(C(=O)CC4)C
  • InChI=InChI=1S/C22H25N3O2/c1-3-21(26)24-19-6-4-5-16-17(12-23-13-18(16)19)14-7-9-20-15(11-14)8-10-22(27)25(20)2/h7,9,11-13,19H,3-6,8,10H2,1-2H3,(H,24,26)/t19-/m1/s1
  • Key:VDEUDSRUMNAXJG-LJQANCHMSA-N

Baxdrostat is an investigational drug that is being evaluated for the treatment of hypertension. [1] It is an aldosterone synthase inhibitor. [2] [3]

References

  1. ↑ "Baxdrostat - CinCor Pharma". AdisInsight. Springer Nature Switzerland AG.
  2. ↑ Dogra S, Shah S, Gitzel L, Pusukur B, Sood A, Vyas AV, Gupta R (July 2023). "Baxdrostat: A Novel Aldosterone Synthase Inhibitor for Treatment Resistant Hypertension". Current Problems in Cardiology. 48 (11) 101918. doi:10.1016/j.cpcardiol.2023.101918. PMID   37399857. S2CID   259320969.
  3. ↑ Awosika A, Cho Y, Bose U, Omole AE, Adabanya U (October 2023). "Evaluating phase II results of Baxdrostat, an aldosterone synthase inhibitor for hypertension". Expert Opinion on Investigational Drugs. 32 (11): 985–995. doi:10.1080/13543784.2023.2276755. PMID   37883217. S2CID   264517675.


This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.